Last deal

Amount

Private Equity

Stage

12.06.2023

Date

1

all rounds

date founded

Financing round

General

About Company
NanoImaging Services, Inc. (NIS) specializes in CryoEM services for Drug Discovery and Development.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2007

Last funding type

Private Equity

IPO status

Private

Description

NIS is the industry leader in cryo-EM, offering imaging services to the pharmaceutical, biotechnology, and nanotechnology industries. They provide high-resolution visualization of biomolecular structures, helping in target identification, formulation, and manufacturing of drugs. NIS focuses on three areas: Target Enablement, Characterization, and Small molecule MicroED. With state-of-the-art facilities and a team of experts, they make cryo-EM accessible to companies of all sizes, accelerating the development of new therapeutics. NIS is committed to expanding their service capacity through acquisitions, automation, talent recruitment, and new service offerings. They are the largest provider of TEM, cryoEM, and microED services in the industrial life science market.
Contacts
Similar Companies
1000
Advancell Advanced In Vitro Cell Technologies

Advancell Advanced In Vitro Cell Technologies

Advanced In Vitro Cell Technologies is a biotech nanomedicine company developing drugs and providing services and reagents.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Medical

Location

Barcelona, Spain

total rounds

1

total raised

$16.23M
Molecular Express

Molecular Express

Molecular Express is a research and development technology company.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology

Location

Rancho Dominguez, Compton, CA, USA
Xtal BioStructures

Xtal BioStructures

Xtal BioStructures is a contract research organization specializing in X-ray crystallography and protein analysis.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Natick, MA, USA
ITSI-Biosciences

ITSI-Biosciences

ITSI-Biosciences LLC provides bioanalytical and mass spectrometry services for various fields.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Johnstown, PA, USA

Financials

Funding Rounds
1
1

Number of Funding Rounds

Their latest funding was raised on 12.06.2023. Their latest investor Ampersand Capital Partners. Their latest round Private Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
Ampersand Capital Partners

Ampersand Capital Partners

Ampersand is a private equity firm focused on investments in Healthcare and Industrial sectors.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Wellesley Hills, Wellesley, MA 02481, USA

total rounds

1

total raised

$18.83M

count Of Investments

65

count Of Exists

28
Co-Investors
Investors
1
1

Number of lead investors

1

Number of investors

Investor 
Lead 
Round 
Partners 
Ampersand Capital Partners

Ampersand Capital Partners

Ampersand is a private equity firm focused on investments in Healthcare and Industrial sectors.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Wellesley Hills, Wellesley, MA 02481, USA

total rounds

1

total raised

$18.83M

count Of Investments

65

count Of Exists

28

David J. Parker

Dave, who has more than 15 years of private equity experience, joined Ampersand in 1994. Dave’s board seats have included Bako, NOVEX, Signature Genomics and Roadrunner. Prior to joining Ampersand, Dave spent five years consulting at Bain and Mercer and four years in corporate lending at Bank of Boston. He holds a B.A. in Government and Economics from Dartmouth and an M.B.A. from Wharton.

current job

Bank Of Boston
Bank Of Boston

People

Employee Profiles
8
Brian Conkle

Brian Conkle

Chief Operating Officer

Philip Mcgilvray

Principal scientist

Sean Thomson

Systems administrator

Peter Glick

Chairman

Bridget Carragher

Founder and Co-Chief Technology Officer

Clint Potter

President

Activity

Recent News
1